vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Duolingo, Inc. (DUOL). Click either name above to swap in a different company.
Duolingo, Inc. is the larger business by last-quarter revenue ($295.5M vs $191.2M, roughly 1.5× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 27.0%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 28.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Duolingo, Inc. is a leading global edtech firm operating a gamified language learning platform. It offers free and premium self-paced courses for over 40 languages, plus language certification, math learning tools, and literacy programs, serving individual learners, schools and corporate clients worldwide.
AXSM vs DUOL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $295.5M |
| Net Profit | — | $35.1M |
| Gross Margin | — | 55.5% |
| Operating Margin | -33.1% | 8.0% |
| Net Margin | — | 11.9% |
| Revenue YoY | 57.4% | 27.0% |
| Net Profit YoY | — | 24.0% |
| EPS (diluted) | — | $0.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $295.5M | ||
| Q4 25 | $196.0M | $282.9M | ||
| Q3 25 | $171.0M | $271.7M | ||
| Q2 25 | $150.0M | $252.3M | ||
| Q1 25 | $121.5M | $230.7M | ||
| Q4 24 | $118.8M | $209.6M | ||
| Q3 24 | $104.8M | $192.6M | ||
| Q2 24 | $87.2M | $178.3M |
| Q1 26 | — | $35.1M | ||
| Q4 25 | $-28.6M | $42.0M | ||
| Q3 25 | $-47.2M | $292.2M | ||
| Q2 25 | $-48.0M | $44.8M | ||
| Q1 25 | $-59.4M | $35.1M | ||
| Q4 24 | $-74.9M | $13.9M | ||
| Q3 24 | $-64.6M | $23.4M | ||
| Q2 24 | $-79.3M | $24.4M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 72.8% | ||
| Q3 25 | — | 72.5% | ||
| Q2 25 | — | 72.4% | ||
| Q1 25 | — | 71.1% | ||
| Q4 24 | — | 71.9% | ||
| Q3 24 | — | 72.9% | ||
| Q2 24 | — | 73.4% |
| Q1 26 | -33.1% | 8.0% | ||
| Q4 25 | -13.8% | 15.4% | ||
| Q3 25 | -27.0% | 12.9% | ||
| Q2 25 | -24.5% | 13.2% | ||
| Q1 25 | -46.9% | 10.2% | ||
| Q4 24 | -61.1% | 6.6% | ||
| Q3 24 | -59.8% | 7.0% | ||
| Q2 24 | -89.5% | 10.5% |
| Q1 26 | — | 11.9% | ||
| Q4 25 | -14.6% | 14.8% | ||
| Q3 25 | -27.6% | 107.5% | ||
| Q2 25 | -32.0% | 17.8% | ||
| Q1 25 | -48.9% | 15.2% | ||
| Q4 24 | -63.1% | 6.6% | ||
| Q3 24 | -61.7% | 12.1% | ||
| Q2 24 | -91.0% | 13.7% |
| Q1 26 | — | $0.72 | ||
| Q4 25 | $-0.55 | $0.99 | ||
| Q3 25 | $-0.94 | $5.95 | ||
| Q2 25 | $-0.97 | $0.91 | ||
| Q1 25 | $-1.22 | $0.72 | ||
| Q4 24 | $-1.54 | $0.31 | ||
| Q3 24 | $-1.34 | $0.49 | ||
| Q2 24 | $-1.67 | $0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $1.1B |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $1.3B |
| Total Assets | $713.6M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $1.1B | ||
| Q4 25 | $322.9M | $1.0B | ||
| Q3 25 | $325.3M | $1.0B | ||
| Q2 25 | $303.0M | $976.2M | ||
| Q1 25 | $300.9M | $884.0M | ||
| Q4 24 | $315.4M | $785.8M | ||
| Q3 24 | $327.3M | $854.4M | ||
| Q2 24 | $315.7M | $888.2M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $88.3M | $1.3B | ||
| Q3 25 | $73.7M | $1.3B | ||
| Q2 25 | $73.1M | $977.0M | ||
| Q1 25 | $53.2M | $893.8M | ||
| Q4 24 | $57.0M | $824.5M | ||
| Q3 24 | $92.9M | $822.5M | ||
| Q2 24 | $102.9M | $766.9M |
| Q1 26 | $713.6M | $2.0B | ||
| Q4 25 | $689.8M | $2.0B | ||
| Q3 25 | $669.3M | $1.9B | ||
| Q2 25 | $639.8M | $1.5B | ||
| Q1 25 | $596.7M | $1.4B | ||
| Q4 24 | $568.5M | $1.3B | ||
| Q3 24 | $561.5M | $1.2B | ||
| Q2 24 | $548.2M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $105.6M |
| Free Cash FlowOCF − Capex | — | $103.0M |
| FCF MarginFCF / Revenue | — | 34.9% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $368.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $105.6M | ||
| Q4 25 | $-18.7M | $107.3M | ||
| Q3 25 | $1.0M | $84.2M | ||
| Q2 25 | $-32.4M | $90.7M | ||
| Q1 25 | $-43.4M | $105.6M | ||
| Q4 24 | $-26.2M | $83.3M | ||
| Q3 24 | $-18.6M | $56.3M | ||
| Q2 24 | $-30.1M | $62.4M |
| Q1 26 | — | $103.0M | ||
| Q4 25 | $-18.7M | $96.6M | ||
| Q3 25 | $988.0K | $79.4M | ||
| Q2 25 | $-32.4M | $89.5M | ||
| Q1 25 | $-43.7M | $104.3M | ||
| Q4 24 | $-26.2M | $81.4M | ||
| Q3 24 | $-18.7M | $53.1M | ||
| Q2 24 | $-30.2M | $56.8M |
| Q1 26 | — | 34.9% | ||
| Q4 25 | -9.6% | 34.1% | ||
| Q3 25 | 0.6% | 29.2% | ||
| Q2 25 | -21.6% | 35.5% | ||
| Q1 25 | -36.0% | 45.2% | ||
| Q4 24 | -22.1% | 38.8% | ||
| Q3 24 | -17.9% | 27.6% | ||
| Q2 24 | -34.6% | 31.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.8% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.3% | 0.6% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.1% | 1.7% | ||
| Q2 24 | 0.1% | 3.1% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | — | 2.56× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 2.02× | ||
| Q1 25 | — | 3.01× | ||
| Q4 24 | — | 5.99× | ||
| Q3 24 | — | 2.41× | ||
| Q2 24 | — | 2.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
DUOL
| Bookings | $283.5M | 96% |
| Other | $12.0M | 4% |
